# STAT+: In win for RFK Jr., FDA advisory panel narrowly votes to allow compounding of unapproved peptides
Canonical URL: https://biopharmsignal.com/news/MARKET/stat-in-win-for-rfk-jr-fda-advisory-panel-narrowly-votes-to-allow-compounding-of-56ccdc64
Ticker: MARKET
Company: MARKET
Source: STAT News
Published: 2026-07-23 20:08 EST
Original Source URL: https://www.statnews.com/2026/07/23/fda-panel-okays-peptides-compound-pharmacies-bpc-157-kpv/?utm_campaign=rss
## Summary

The panel recommended allowing compounding pharmacies to produce popular but unproven BPC-157 and KPV peptides.

## Article Body
Lizzy leads STAT’s coverage of the FDA. Her stories explore the relationship between politics and science at the FDA, industry influence, and the agency’s ability to protect and promote public health. Confidential tips can be sent on Signal at lizzylaw.53.

In a win for peptide proponents and for health secretary Robert F. Kennedy Jr., an advisory panel to the Food and Drug Administration recommended on Thursday that compounding pharmacies be allowed to manufacture the drugs BPC-157 and KPV.

The FDA will vote on two other peptides, TB-500 and MOTS-c, later on Thursday afternoon, and on additional compounds on Friday.

The votes are not binding, and the FDA will ultimately decide whether to lift current restrictions on these peptides and make them more easily accessible to people who’ve been turning to the little-researched but highly popular drugs to improve their health. It’s unusual for the FDA to go against the recommendations of the Pharmacy Compounding Advisory Committee, or PCAC, but it has happened at least once before.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe
## Recent Company News
- 2026-07-23 20:08 EST — [STAT+: In win for RFK Jr., FDA advisory panel narrowly votes to allow compounding of unapproved peptides](https://biopharmsignal.com/news/MARKET/stat-in-win-for-rfk-jr-fda-advisory-panel-narrowly-votes-to-allow-compounding-of-56ccdc64) — Source: STAT News
- 2026-07-23 17:25 EST — [U.S. health officials are investigating a new outbreak of a diarrhea-causing parasite](https://biopharmsignal.com/news/MARKET/u-s-health-officials-are-investigating-a-new-outbreak-of-a-diarrhea-causing-para-9e98f2f3) — Source: STAT News
- 2026-07-23 16:33 EST — [STAT+: European regulators take steps to bolster clinical trial transparency](https://biopharmsignal.com/news/MARKET/stat-european-regulators-take-steps-to-bolster-clinical-trial-transparency-73aade26) — Source: STAT News
- 2026-07-23 16:23 EST — [STAT+: Popular insulin product enters shortage as other pens leave market](https://biopharmsignal.com/news/MARKET/stat-popular-insulin-product-enters-shortage-as-other-pens-leave-market-c3a6a199) — Source: STAT News
- 2026-07-23 16:18 EST — [Senate health panel delays vote on CDC nominee](https://biopharmsignal.com/news/MARKET/senate-health-panel-delays-vote-on-cdc-nominee-6cfcdaaa) — Source: STAT News
## Related News
- 2026-07-23 20:05 EST — IMVT — [Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026](https://biopharmsignal.com/news/IMVT/immunovant-to-report-financial-results-for-the-first-quarter-ended-june-30-2026--73653d45)
- 2026-07-23 17:25 EST — MARKET — [U.S. health officials are investigating a new outbreak of a diarrhea-causing parasite](https://biopharmsignal.com/news/MARKET/u-s-health-officials-are-investigating-a-new-outbreak-of-a-diarrhea-causing-para-9e98f2f3)
- 2026-07-23 16:33 EST — MARKET — [STAT+: European regulators take steps to bolster clinical trial transparency](https://biopharmsignal.com/news/MARKET/stat-european-regulators-take-steps-to-bolster-clinical-trial-transparency-73aade26)
- 2026-07-23 16:30 EST — BRLI — [OPKO Health to Report Second Quarter 2026 Financial Results on July 27, 2026](https://biopharmsignal.com/news/BRLI/opko-health-to-report-second-quarter-2026-financial-results-on-july-27-2026-4b38e04c)
- 2026-07-23 16:23 EST — MARKET — [STAT+: Popular insulin product enters shortage as other pens leave market](https://biopharmsignal.com/news/MARKET/stat-popular-insulin-product-enters-shortage-as-other-pens-leave-market-c3a6a199)